Optimizing immunogenicity assays can be accelerated through a systematic experimental approach.

Developing robust anti-drug antibody (ADA) assays often requires evaluating multiple variables to achieve the desired sensitivity, drug tolerance, and reproducibility. This poster demonstrates how Design of Experiments (DOE) was applied to streamline the optimization of an electrochemiluminescence (ECL)-based ADA assay, improving assay performance while reducing development time.

Key highlights include:

• Application of Design of Experiments (DOE) to ADA assay development
• Optimization of key assay parameters to improve sensitivity and drug tolerance
• Strategies for enhancing assay reproducibility and analytical performance
• Development of an ECL-based immunogenicity assay for preclinical and clinical studies
• Practical insights for reducing assay development time through structured experimental design

As immunogenicity testing continues to evolve, efficient assay optimization is essential for delivering reliable results while accelerating development timelines. Learn how a DOE-based approach can support the development of robust, fit-for-purpose ADA assays for regulated bioanalysis.